TrialAnnals of the rheumatic diseases2024

Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials.

Tina Baker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.